In a nutshell This study aimed to investigate the impact of a pharmaceutical care program on the safety and effectiveness of ibrutinib in patients with B-cell non-Hodgkin's lymphoma (NHL). This study concluded that the management of ibrutinib treatment by using a pharmaceutical care program results in improved survival and better tolerance than...
Read More
In a nutshell This review aimed to discuss the toxicities of ibrutinib (Imbruvica) treatment and how to manage them. This review concluded that patients should be regularly monitored for toxicities and actively treated to reduce side effects and avoid disruption to treatment. Some background Ibrutinib is a type of targeted therapy known as a...
Read More
In a nutshell This study aimed to investigate the risk of infection with ibrutinib treatment in B-cell malignancies such as lymphoma. This study concluded that ibrutinib was associated with a higher risk of infections in these patients. Some background B-cell malignancies such as non-Hodgkin lymphoma (NHL) lead to an increased risk of...
Read MoreIn a nutshell This study is looking for patients with relapsed or unresponsive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to test IOV-2001, a treatment that boosts cancer-killing immune cells. The main outcome that will be measured is how well patients respond to treatment. This study is recruiting in Columbus, OH, the...
Read More
In a nutshell The study aimed to identify cardiovascular (heart and blood vessel) adverse drug reactions (CV-ADR) associated with ibrutinib treatment. This study concluded that severe and sometimes fatal cardiac events occur in patients exposed to ibrutinib. Some background Ibrutinib (Imbruvica) is a targeted therapy that can be used for...
Read More
In a nutshell The study aimed to identify cardiovascular (heart and blood vessel) adverse drug reactions (CV-ADR) associated with ibrutinib treatment. This study concluded that severe and sometimes fatal cardiac events occur in patients exposed to ibrutinib. Some background Ibrutinib (Imbruvica) is a targeted therapy that can be used for...
Read More
In a nutshell This study looked at the evidence for the safety of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). Researchers found that this drug is safe to use in these patients. Some background Leukemia and lymphoma are types of cancer of the bone marrow. They can lead to...
Read More
In a nutshell This study looked at the risk of infections associated with ibrutinib (Imbruvica) used in the treatment of leukemia and lymphoma. Researchers found that patients receiving ibrutinib are at risk of serious infections. Some background Ibrutinib is a drug which targets certain proteins on cancer cells to stop them from working. It is often...
Read MoreIn a nutshell This study investigated the long-term safety and effectiveness of ibrutinib (Imbruvica) plus rituximab (Rituxan) for relapsed or refractory (does not respond to treatment) mantle cell lymphoma. This study concluded that this treatment is safe and effective for relapsed or refractory mantle cell lymphoma. Some background Mantle cell...
Read More
In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with chronic lymphocytic leukemia (CLL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of...
Read More
